StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Jefferies on Viridian Therapeutic (VRDN): bears to argue commercial oppy not clean, bulls see de-risk
March 30, 2026 8:24 AM
Jefferies analyst Faisal Khurshid reiterated a Buy rating and $45.00 price target on Viridian Therapeutic (NASDAQ: VRDN)The analyst commented, "Topline ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
